Researchers discover new genetic mutation linked to osteonecrosis of the hip
Scientists at the Research Institute of McGill University Health Centre (RI-MUHC) have discovered a new genetic mutation linked to osteonecrosis of the hip, specifically the femoral head – the spherical-shaped mass at the top of the femur. This breakthrough could allow doctors to identify and treat the disease before symptoms arise and potentially avoid hip replacements.
World-renowned pain specialist and medical cannabis researcher Dr. Mark Ware, director of clinical research at the Alan Edwards Pain Management Unit of the McGill University Health Centre (MUHC), has been nominated vice-chair of an important federal task force that will provide guidance to the Canadian government as it prepares to introduce legislation to legalize marijuana in spring 2017.
Secondary Contact Information
By Julie Robert, McGill University Health Centre
Millions of people today take statins to help lower their cholesterol level.
The McGill Global Health Programs is proud to support this special lecture from the Infectious Diseases and Immunity in Global Health (IDIGH) Program Seminar Series featuring Dr. Evan Lee, VP Global Health at Eli Lilly. Dr.
It may be surprising, but Canadians who live in densely-populated areas where stores, banks, schools and other services are close by do not walk as much as they should.
Landmark Clinical Trial of a Novel Combination Treatment for Type 1 Diabetes Begins at Jewish General Hospital and McGill University Health Centre
There are believed to be around 1.5 million different species of fungus on Earth, but one mold, known as Aspergillus fumigatus, causes the majority of cases of invasive aspergillosis – a devastating illness that kills 90 per cent of patients with weakened immune systems or lung diseases.
Discovery explains how Leishmania parasite boosts its infection
McGill puts the spotlight on the past, present and future of the “hospital”
It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre (RI-MUHC) and University of Alberta could be a game changer for patients, improving both quality of life and longevity. The research team discovered a new gene involved in muscle wasting that could be a good target for drug development.